150 related articles for article (PubMed ID: 35617790)
1. Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors.
Xu T; Meng JR; Cheng W; Liu JZ; Chu J; Zhang Q; Ma N; Bai LP; Guo Y
Bioorg Med Chem; 2022 Aug; 67():116838. PubMed ID: 35617790
[TBL] [Abstract][Full Text] [Related]
2. Semisynthesis, biological activities, and mechanism studies of Mannich base analogues of magnolol/honokiol as potential α-glucosidase inhibitors.
Chu J; Yang R; Cheng W; Cui L; Pan H; Liu J; Guo Y
Bioorg Med Chem; 2022 Dec; 75():117070. PubMed ID: 36327695
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Biological Evaluation of Honokiol Derivatives Bearing 3-((5-phenyl-1,3,4-oxadiazol-2-yl)methyl)oxazol-2(3H)-ones as Potential Viral Entry Inhibitors against SARS-CoV-2.
Guo Y; Meng JR; Liu JZ; Xu T; Zheng ZY; Jiang ZH; Bai LP
Pharmaceuticals (Basel); 2021 Aug; 14(9):. PubMed ID: 34577585
[TBL] [Abstract][Full Text] [Related]
4. Identification of natural compounds as SARS-CoV-2 entry inhibitors by molecular docking-based virtual screening with bio-layer interferometry.
Zhang D; Hamdoun S; Chen R; Yang L; Ip CK; Qu Y; Li R; Jiang H; Yang Z; Chung SK; Liu L; Wong VKW
Pharmacol Res; 2021 Oct; 172():105820. PubMed ID: 34403732
[TBL] [Abstract][Full Text] [Related]
5. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
[TBL] [Abstract][Full Text] [Related]
6. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
7. Semisynthesis and biological evaluation of novel honokiol thioethers against colon cancer cells HCT116 via inhibiting the transcription and expression of YAP protein.
Yang R; Fu X; Fan J; Wang T; Song J; Xu T; Guo Y; Zhang SY
Bioorg Med Chem; 2024 Jun; 107():117762. PubMed ID: 38759254
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
9. Identifying compounds that prevent the binding of the SARS-CoV-2 S-protein to ACE2.
Benítez-Cardoza CG; Vique-Sánchez JL
Comput Biol Med; 2021 Sep; 136():104719. PubMed ID: 34358993
[TBL] [Abstract][Full Text] [Related]
10. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
Zhan Y; Ta W; Tang W; Hua R; Wang J; Wang C; Lu W
Drug Dev Res; 2021 Dec; 82(8):1124-1130. PubMed ID: 33847382
[TBL] [Abstract][Full Text] [Related]
11. Novel 1,3,4-thiadiazole/oxadiazole-linked honokiol derivatives suppress cancer via inducing PI3K/Akt/mTOR-dependent autophagy.
Xu T; Tian W; Zhang Q; Liu J; Liu Z; Jin J; Guo Y; Bai LP
Bioorg Chem; 2021 Oct; 115():105257. PubMed ID: 34426156
[TBL] [Abstract][Full Text] [Related]
12. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
13. Selection of Bis-Indolyl Pyridines and Triphenylamines as New Inhibitors of SARS-CoV-2 Cellular Entry by Modulating the Spike Protein/ACE2 Interfaces.
Lapaillerie D; Charlier C; Guyonnet-Dupérat V; Murigneux E; Fernandes HS; Martins FG; Magalhães RP; Vieira TF; Richetta C; Subra F; Lebourgeois S; Charpentier C; Descamps D; Visseaux B; Weigel P; Favereaux A; Beauvineau C; Buron F; Teulade-Fichou MP; Routier S; Gallois-Montbrun S; Meertens L; Delelis O; Sousa SF; Parissi V
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0008322. PubMed ID: 35861550
[TBL] [Abstract][Full Text] [Related]
14. Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2.
Lee RK; Li TN; Chang SY; Chao TL; Kuo CH; Pan MY; Chiou YT; Liao KJ; Yang Y; Wu YH; Huang CH; Juan HF; Hsieh HP; Wang LH
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409412
[TBL] [Abstract][Full Text] [Related]
15. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
16. Anti-Entry Activity of Natural Flavonoids against SARS-CoV-2 by Targeting Spike RBD.
Meng JR; Liu J; Fu L; Shu T; Yang L; Zhang X; Jiang ZH; Bai LP
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680200
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region.
Pourmand S; Zareei S; Shahlaei M; Moradi S
Comput Biol Med; 2022 Jul; 146():105625. PubMed ID: 35688710
[TBL] [Abstract][Full Text] [Related]
18. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.
Gangadevi S; Badavath VN; Thakur A; Yin N; De Jonghe S; Acevedo O; Jochmans D; Leyssen P; Wang K; Neyts J; Yujie T; Blum G
J Phys Chem Lett; 2021 Feb; 12(7):1793-1802. PubMed ID: 33577324
[TBL] [Abstract][Full Text] [Related]
19. In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.
Bharathi M; Sivamaruthi BS; Kesika P; Thangaleela S; Chaiyasut C
Mar Drugs; 2022 Feb; 20(2):. PubMed ID: 35200677
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, In vitro α-Glucosidase Inhibitory Potential and Molecular Docking Studies of 2-Amino-1,3,4-Oxadiazole Derivatives.
Ullah H; Rahim F; Taha M; Hussain R; Wadood A; Nawaz M; Wahab Z; Kanwal ; Khan KM
Med Chem; 2020; 16(6):724-734. PubMed ID: 31195948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
